Neurocrine Biosciences (NBIX) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free NBIX Stock Alerts $135.41 -1.25 (-0.91%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 8:42 AM | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $5,338,400.00 in StockMay 31 at 8:32 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Trading Down 5.3%May 31 at 4:56 AM | marketbeat.comNorges Bank Acquires New Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Norges Bank bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 271,182 shares of the company's stock, valued at approximately $35,731May 31 at 4:02 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Rating Reaffirmed by WedbushMay 30 at 8:17 PM | marketbeat.comStephen A. Sherwin Sells 40,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the sale, the director now owns 26,504 shares in the company, valued at $3,537,223.84. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.May 30 at 1:56 PM | marketbeat.comWeiss Asset Management LP Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Weiss Asset Management LP purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 14,496 shares of the company's stock, valued at approximately $1,May 29 at 4:53 PM | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Neurocrine (NBIX)May 29 at 4:01 PM | prnewswire.comNeurocrine Biosciences to Participate at Investor Conferences in JuneMay 29 at 1:56 PM | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 5.3%Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 5.3%May 29 at 2:56 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $193.00 by Analysts at UBS GroupMay 29 at 12:43 AM | markets.businessinsider.comNeurocrine Biosciences CEO Kevin Gorman To Retire; Appoints Kyle Gano As CEO-electMay 28, 2024 | marketwatch.comNeurocrine Biosciences Names Kyle Gano as Next CEOMay 28, 2024 | reuters.comNeurocrine founder-CEO Gorman to retire in OctoberMay 28, 2024 | prnewswire.comNeurocrine Biosciences Announces CEO Succession PlanMay 28, 2024 | markets.businessinsider.comKey Takeaways From Neurocrine Biosciences Analyst RatingsMay 28, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $193.00 at UBS GroupUBS Group raised their price target on shares of Neurocrine Biosciences from $174.00 to $193.00 and gave the stock a "buy" rating in a research note on Tuesday.May 28, 2024 | prnewswire.comNeurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024May 26, 2024 | marketbeat.comPrimecap Management Co. CA Purchases 6,738 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Primecap Management Co. CA raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 398,323 shares of the company's stock aftMay 25, 2024 | marketbeat.comWestfield Capital Management Co. LP Sells 54,855 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Westfield Capital Management Co. LP decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 594,437 shares of the company's stock after selling 54,855 shares during theMay 24, 2024 | marketbeat.comAssetmark Inc. Purchases 8,678 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Assetmark Inc. raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 30.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 36,955 shares of the company's stock after purchasing an additional 8,678 shares during the period. AssMay 23, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Clearbridge Investments LLCClearbridge Investments LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 9.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 340,802 shares ofMay 22, 2024 | marketbeat.comING Groep NV Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)ING Groep NV purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,300 shares of the company's stock, valued at approximatelyMay 22, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Shalini Sharp Sells 1,106 SharesMay 21, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $156,941.40 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Shalini Sharp sold 1,106 shares of Neurocrine Biosciences stock in a transaction on Friday, May 17th. The stock was sold at an average price of $141.90, for a total transaction of $156,941.40. Following the completion of the sale, the director now owns 994 shares of the company's stock, valued at approximately $141,048.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.May 21, 2024 | prnewswire.comNeurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) CapsulesMay 21, 2024 | marketbeat.comTrexquant Investment LP Acquires 82,139 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Trexquant Investment LP lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1,364.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,160 sharesMay 20, 2024 | marketbeat.comGW&K Investment Management LLC Sells 18,829 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)GW&K Investment Management LLC lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 535,962 shaMay 19, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Has $14.40 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Robeco Institutional Asset Management B.V. cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 29.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,321 shares ofMay 18, 2024 | marketbeat.comBrown Advisory Inc. Raises Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Brown Advisory Inc. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,113,413 shares of the company's stock after purchasinMay 18, 2024 | marketbeat.comFiera Capital Corp Raises Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Fiera Capital Corp boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 516,865 shares of the company's stock after acquiring an additional 5,497 sharMay 17, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 12,500 Shares of StockMay 16, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $1,695,375.00 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Gary A. Lyons sold 12,500 shares of the company's stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total value of $1,695,375.00. Following the completion of the transaction, the director now directly owns 116,947 shares of the company's stock, valued at approximately $15,861,521.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.May 16, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Principal Financial Group Inc.Principal Financial Group Inc. increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 10.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 418,245 shares of the company's stock after purchasing anMay 15, 2024 | marketbeat.comM&G Investment Management Ltd. Acquires 5,781 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)M&G Investment Management Ltd. grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,615 shares of the company's stock after purchasing an additional 5,7May 14, 2024 | nasdaq.comEvercore ISI Group Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform RecommendationMay 14, 2024 | prnewswire.comNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024May 14, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Earns Outperform Rating from Analysts at Evercore ISIEvercore ISI assumed coverage on Neurocrine Biosciences in a report on Tuesday. They issued an "outperform" rating and a $175.00 price target for the company.May 14, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Jump Financial LLCJump Financial LLC increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 114.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,905 shares of thMay 13, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 10.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 307,630 shares of the company's stock afMay 11, 2024 | marketbeat.comVictory Capital Management Inc. Acquires 47,389 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Victory Capital Management Inc. boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 67.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 117,221 shares of the company's stock after buying an additional 47,389 shareMay 9, 2024 | finance.yahoo.comHow Neurocrine Is Stacking Up Wins In 2024 — And Outperforming PeersMay 9, 2024 | finance.yahoo.comHow Neurocrine, An IBD 50 Stock, Is Stacking Up Wins In 2024 — And Outperforming PeersMay 9, 2024 | prnewswire.comNeurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024May 9, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 273 Shares of StockMay 9, 2024 | prnewswire.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy AdultsMay 9, 2024 | globenewswire.comNxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 8, 2024 | marketbeat.comIngrid Delaet Sells 273 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 273 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the completion of the transaction, the insider now directly owns 7,507 shares of the company's stock, valued at $1,055,108.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.May 8, 2024 | marketbeat.comSawgrass Asset Management LLC Invests $13.12 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Sawgrass Asset Management LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 99,557 shares of the companyMay 8, 2024 | prnewswire.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 7, 2024 | marketbeat.comLisanti Capital Growth LLC Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Lisanti Capital Growth LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 74.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,755 shares of the company's stock after selling 19,875 shares during the period Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. NBIX Media Mentions By Week NBIX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.650.79▲Average Medical News Sentiment NBIX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼239▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Repligen News Today Exelixis News Today Halozyme Therapeutics News Today Denali Therapeutics News Today Adaptive Biotechnologies News Today Biogen News Today Bio-Techne News Today Qiagen News Today Vaxcyte News Today argenx News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
